Rule 2.10 Announcement


 
TIDMBII 
 
20 January 2011 
 
                       BIOCOMPATIBLES INTERNATIONAL PLC 
 
                      ("Biocompatibles" or the "Company") 
 
Rule 2.10 Announcement 
 
In accordance with Rule 2.10 of the City Code on Takeovers and Mergers, 
Biocompatibles International plc ("Biocompatibles") announces that it 
has issued 1,583,291 ordinary shares of 21 53/94 pence. 
 
 
Accordingly, the issued securities of Biocompatibles comprises 40,965,665 
ordinary shares of 21 53/94 pence. 
 
 
The ISIN for the ordinary shares is GB00B0L2JD04. 
 
Contact: 
 
Biocompatibles +44 (0)1252 732645 
 
Ian Ardill, Finance Director 
 
Lygia Jones, Assistant Company Secretary 
 
Dealing Disclosure Requirements 
 
Following the announcement made on Monday, 20 September 2010 that the Company 
 
is in an offer period for the purposes of the Takeover Code, the Company is 
 
required to restate the following: 
 
Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of 
 
any class of relevant securities of an offeree company or of any paper offeror 
 
(being any offeror other than an offeror in respect of which it has been 
 
announced that its offer is, or is likely to be, solely in cash) must make an 
 
Opening Position Disclosure following the commencement of the offer period and, 
 
if later, following the announcement in which any paper offeror is first 
 
identified. An Opening Position Disclosure must contain details of the person's 
 
interests and short positions in, and rights to subscribe for, any relevant 
 
securities of each of (i) the offeree company and (ii) any paper offeror(s). An 
 
Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be 
 
made by no later than 3.30 pm (London time) on the 10th business day following 
 
the commencement of the offer period and, if appropriate, by no later than 3.30 
 
pm (London time) on the 10th business day following the announcement in which 
 
any paper offeror is first identified. Relevant persons who deal in the 
 
relevant securities of the offeree company or of a paper offeror prior to the 
 
deadline for making an Opening Position Disclosure must instead make a Dealing 
 
Disclosure. 
 
Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% 
 
or more of any class of relevant securities of the offeree company or of any 
 
paper offeror must make a Dealing Disclosure if the person deals in any 
 
relevant securities of the offeree company or of any paper offeror. A Dealing 
 
Disclosure must contain details of the dealing concerned and of the person's 
 
interests and short positions in, and rights to subscribe for, any relevant 
 
securities of each of (i) the offeree company and (ii) any paper offeror, save 
 
to the extent that these details have previously been disclosed under Rule 8. A 
 
Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no 
 
later than 3.30 pm (London time) on the business day following the date of the 
 
relevant dealing. If two or more persons act together pursuant to an agreement 
 
or understanding, whether formal or informal, to acquire or control an interest 
 
in relevant securities of an offeree company or a paper offeror, they will be 
 
deemed to be a single person for the purpose of Rule 8.3. 
 
Opening Position Disclosures must also be made by the offeree company and by 
 
any offeror and Dealing Disclosures must also be made by the offeree company, 
 
by any offeror and by any persons acting in concert with any of them (see Rules 
 
8.1, 8.2 and 8.4). 
 
Details of the offeree and offeror companies in respect of whose relevant 
 
securities Opening Position Disclosures and Dealing Disclosures must be made 
 
can be found in the Disclosure Table on the Takeover Panel's website at 
 
www.thetakeoverpanel.org.uk, including details of the number of relevant 
 
securities in issue, when the offer period commenced and when any offeror was 
 
first identified. If you are in any doubt as to whether you are required to 
 
make an Opening Position Disclosure or a Dealing Disclosure, you should contact 
 
the Panel's Market Surveillance Unit on +44 (0)20 7638 0129. 
 
Biocompatibles International plc (www.biocompatibles.com) 
 
Biocompatibles International plc is a leading medical technology company in the 
 
field of drug-device combination products. 
 
The Oncology Products Division supplies medical devices from facilities in 
 
Farnham, UK and Oxford, CT. These include Drug-Eluting Bead Products which are 
 
used in more than 40 countries for the treatment of primary liver cancer (HCC), 
 
liver metastases from colorectal cancer, and other cancers; and Brachytherapy 
 
products (Radiation-Delivering Seeds) which are used in the treatment of 
 
prostate cancer. Our distribution partners include AngioDynamics Inc., Terumo 
 
Corporation and Eisai Co. Ltd. We have a clinical collaboration agreement with 
 
Bayer Healthcare Pharmaceuticals Inc. 
 
Our Licensing Division includes CellMed, in Alzenau, Germany, which is 
 
developing a Drug-Eluting Bead product for the treatment of stroke, based on 
 
proprietary stem cell technology; a GLP-1 analogue for the treatment of 
 
diabetes and obesity partnered with AstraZeneca; and a cosmetic Dermatology 
 
Bead partnered with Merz Pharmaceuticals GmbH. We also have a PC Licensing 
 
agreement with Medtronic Inc. in the field of Drug-Eluting Stents. 
 
This news release contains forward-looking statements that reflect 
 
Biocompatibles' current expectation regarding future events. Forward-looking 
 
statements involve risks and uncertainties. Actual events could differ 
 
materially from those projected herein and depend on a number of factors 
 
including the success of Biocompatibles' research strategy, the applicability 
 
of the discoveries made therein, the successful and timely completion of 
 
clinical studies and the uncertainties related to the regulatory and 
 
commercialisation processes. 
 
 
 
END
Biocompatibles (LSE:BII)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024